MDRX Stock Cash Flow Statements

Allscripts Healthcare Solutions Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Allscripts Healthcare Solutions Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-05-31	2010-02-28	2009-11-30	2009-08-31	2009-05-31	2009-02-28	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31

cash flows from operating activities:
net income	14,528,000	-64,026,000	22,857,000	87,275,000	16,180,000	21,926,000	9,057,000	727,824,000	542,000	-7,605,000	-20,354,000	-163,632,000	-157,907,000	-7,977,000	385,896,000	-23,846,000	74,272,000	-28,515,000	14,863,000	-17,462,000	-143,011,000	-8,565,000	2,882,000	157,000	-2,136,000	2,127,000	16,377,000	-5,133,000	-3,216,000	-10,084,000	-2,178,000	-25,763,000	-17,770,000	-20,742,000	-20,618,000	-48,940,000	-22,876,000	-11,592,000	-24,322,000	9,375,000	7,981,000	5,813,000	24,136,000	20,984,000	15,876,000	12,613,000	15,689,000	18,470,000	15,779,000	12,932,000	13,361,000		4,016,000	2,352,000	80,000	5,944,000	4,124,000	6,028,000	4,467,000	4,483,000	3,262,000	2,827,000	1,323,000	3,403,000	2,940,000	2,033,000	1,334,000	1,403,000	742,000	696,000	267,000	116,000
less: income from discontinued operations	3,603,000	-67,288,000	4,386,000	-8,000	-14,000	21,000	464,000					0	0	0
income from continuing operations	10,925,000	3,262,000	18,471,000	87,283,000	16,194,000	21,905,000	8,593,000					-163,632,000	-157,907,000	-7,977,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	13,813,000	14,364,000	14,101,000	43,148,000	44,276,000	44,687,000	44,026,000	38,587,000	49,158,000	52,432,000	52,092,000	152,250,000	100,603,000	50,126,000	-8,483,000	68,612,000	66,305,000	65,912,000	63,429,000	53,811,000	51,603,000	49,694,000	51,917,000	43,897,000	42,124,000	34,452,000	36,525,000	40,998,000	41,827,000	41,661,000	42,717,000	42,819,000	43,600,000	45,127,000	47,018,000	46,832,000	44,138,000	40,827,000	39,652,000	37,697,000	37,669,000	35,216,000	35,164,000	33,524,000	32,846,000	30,866,000	9,570,000	8,997,000	9,085,000	8,870,000	8,131,000	8,488,000	7,885,000	7,670,000	6,721,000	6,378,000	5,989,000	4,661,000	4,440,000	4,429,000	4,489,000	4,803,000	2,734,000	1,746,000	1,657,000	1,556,000	1,569,000	1,405,000	1,145,000	1,218,000	1,204,000	1,101,000
non-cash lease expense	-103,000	-1,963,000	-3,223,000	-811,000	-521,000
stock-based compensation expense	4,553,000	9,024,000	6,324,000	9,308,000	8,777,000	8,383,000	8,701,000	8,105,000	8,811,000	7,166,000	9,954,000	29,563,000	21,790,000	11,658,000	4,828,000	9,848,000	8,010,000	11,952,000	10,629,000	9,679,000	10,515,000	7,946,000	13,160,000	9,660,000	10,138,000	9,919,000	7,438,000	8,908,000	9,197,000	9,120,000	7,051,000	10,055,000	12,078,000	10,070,000	8,416,000	10,484,000	10,106,000	8,004,000	12,663,000	8,807,000	9,929,000	7,727,000	11,597,000	9,934,000	10,474,000	8,747,000	2,838,000	4,261,000	4,424,000	3,326,000	2,618,000	2,103,000	1,679,000	1,613,000	1,959,000	1,018,000	1,510,000	624,000	656,000	888,000	617,000	416,000	407,000	558,000
deferred taxes	-2,511,000	16,575,000	-17,042,000	-449,000	-1,550,000	1,022,000	-1,122,000	-6,205,000	-202,000	5,292,000	-2,160,000	-3,066,000	-1,506,000	6,000	9,491,000	-5,935,000	5,636,000	-5,048,000	-50,463,000	-665,000	-3,089,000	-1,570,000	-18,423,000	-2,638,000	-1,198,000	-362,000	-4,529,000	3,382,000	-110,000	-949,000	-6,052,000	-839,000	2,437,000	4,398,000	-12,343,000	-2,898,000	-14,559,000	-14,080,000	-13,731,000	-6,101,000	3,714,000	3,338,000	6,971,000	11,637,000	11,892,000	2,895,000	11,093,000	9,793,000	7,385,000	3,291,000			1,390,000	1,294,000	1,007,000	892,000	2,297,000	3,168,000	2,960,000	2,802,000	2,003,000
impairment of assets and long-term investments	0			9,000
equity in net income of unconsolidated investments	617,000						-22,000					-540,000	-154,000	64,000	270,000	177,000
gain on sale of businesses				-7,000								0	0		0	0
other income					-2,264,000
changes in operating assets and liabilities
accounts receivable and contract assets	43,536,000	2,546,000	26,205,000	-5,057,000	-34,120,000	380,000	33,795,000	-29,074,000	16,384,000	42,193,000	5,660,000	53,886,000	42,256,000	32,307,000	-117,185,000	-3,360,000	-23,369,000	34,780,000
prepaid expenses and other assets	19,450,000	4,817,000	5,431,000	4,708,000	25,403,000	-20,252,000	7,935,000	-38,707,000	15,194,000	-30,574,000	19,669,000	615,000	-16,691,000	3,658,000	-46,917,000	-8,334,000	3,692,000	-4,259,000	20,759,000	2,292,000	-4,767,000	-4,464,000	10,384,000	458,000	4,738,000	-1,815,000	5,884,000	5,687,000	8,003,000	-1,960,000	9,142,000	-5,085,000	-13,458,000	2,363,000	1,849,000	-3,624,000	-8,874,000	-12,832,000	-11,035,000	5,938,000	-505,000	-8,828,000	-13,379,000	-2,244,000	-8,590,000	-8,812,000		-5,812,000					-1,345,000													-1,238,000	1,314,000	68,000	-689,000	320,000	1,042,000
accounts payable	-4,224,000	15,036,000	10,210,000	-5,058,000	-4,869,000	-76,000	-8,726,000	-17,376,000	-21,980,000	-3,664,000	-23,967,000	27,571,000	16,285,000	7,382,000	-38,270,000	-305,000	15,294,000	4,122,000	-20,922,000	5,738,000	-5,699,000	2,869,000	14,115,000	10,590,000	-1,246,000	16,997,000	-9,903,000	-1,569,000	-12,298,000	11,817,000	-15,595,000	9,822,000	4,718,000	-889,000	15,087,000	-12,396,000	-632,000	21,735,000	-4,327,000	-8,230,000	585,000	15,412,000	900,000	-7,208,000	50,000	-2,288,000	9,928,000	2,535,000								339,000	2,428,000						1,052,000						1,108,000	-430,000	-22,000	-940,000
accrued expenses	-11,386,000	-591,000	13,031,000	341,000	3,237,000	23,626,000	-5,233,000	500,000	-5,537,000	-8,049,000	10,022,000	145,450,000	146,841,000	-4,847,000	31,667,000	8,458,000	-12,900,000	13,259,000	10,827,000	-1,009,000	380,000	-5,567,000	10,333,000	-134,000	-3,544,000	-5,165,000	-5,185,000	-2,861,000	437,000	-15,365,000	-647,000	-9,619,000	1,754,000	-14,255,000	4,429,000	3,349,000	-4,714,000	-7,616,000	21,313,000	-14,259,000	-1,054,000	-2,603,000	12,804,000	-1,815,000	8,602,000	2,707,000	7,096,000	3,001,000					2,518,000	1,666,000	283,000				3,021,000			-549,000	2,066,000	1,462,000	-828,000	2,500,000	552,000	1,462,000	1,075,000	-429,000	444,000	1,407,000
accrued compensation and benefits	1,294,000	10,076,000	-13,291,000	-521,000	-900,000	10,020,000	-34,633,000	18,828,000	17,061,000	14,339,000	-736,000	-43,426,000	-47,284,000	-39,525,000	18,313,000	-3,926,000	20,127,000	-21,074,000	16,076,000	8,032,000	3,399,000	-5,501,000	8,827,000	-1,529,000	13,525,000	-24,929,000	14,929,000	7,058,000	-594,000	-11,136,000	-4,648,000	2,312,000	-181,000	-27,027,000	21,169,000	11,384,000	80,000	849,000	14,729,000	2,041,000	-331,000	-3,338,000	433,000	-5,171,000	-4,271,000	-5,757,000	3,085,000	2,742,000
deferred revenue	-32,909,000	-6,804,000	-28,352,000	-1,830,000	4,466,000	-14,853,000	-1,475,000	55,487,000	-11,449,000	-16,095,000	724,000	-138,639,000	-77,342,000	-17,107,000	117,605,000	-26,663,000	-11,613,000	-21,319,000	107,380,000	-6,262,000	-23,764,000	48,687,000	-8,865,000	-7,036,000	-11,770,000	49,393,000	23,132,000	-12,828,000	-19,172,000	29,240,000	12,377,000	-12,009,000	-21,507,000	54,248,000	-24,742,000	-13,436,000	1,143,000	35,462,000	-11,165,000	-6,102,000	-8,089,000	28,570,000	24,887,000	-7,715,000	26,147,000	29,409,000	405,000	25,136,000	-7,981,000	532,000	-4,723,000		7,133,000	-4,975,000	9,649,000	2,846,000	2,471,000	-4,949,000	8,013,000				3,313,000	2,203,000			2,490,000	848,000	1,341,000	2,065,000	-606,000
other liabilities	-860,000	-22,820,000	2,022,000	-3,409,000	326,000	1,844,000	1,444,000	3,624,000	95,000	-1,318,000	2,933,000	-701,000	-2,670,000	1,380,000	13,879,000	-831,000	-3,844,000	2,887,000	1,650,000	6,211,000	7,680,000	-997,000	-1,085,000	-1,134,000	1,052,000	54,000	907,000	-1,258,000	215,000	-47,000	-1,556,000	-72,000	-1,044,000	-4,353,000	-7,396,000	-3,115,000	-4,775,000	-576,000	1,670,000	92,000	-335,000	929,000	-1,196,000	939,000	-1,038,000	605,000		231,000												-51,000	-29,000			-41,000	27,000	91,000	79,000		-27,000	-54,000	13,000
net cash from operating activities - continuing operations	42,341,000	42,149,000	34,511,000	66,317,000	56,868,000	69,244,000	55,911,000	-59,572,000	52,967,000	22,646,000	-3,708,000	63,944,000	28,090,000	35,816,000
net cash from operating activities - discontinued operations	-14,200,000	-43,784,000	34,750,000	-1,273,000	-978,000	-270,181,000	-51,336,000	-119,048,000	0	0	0	-30,000,000	-30,000,000	-30,000,000
net cash from operating activities	28,141,000	-1,635,000	69,261,000	65,044,000	55,890,000	-200,937,000	4,575,000	-178,620,000	52,967,000	22,646,000	-3,708,000	33,944,000	-1,910,000	5,816,000	-13,663,000	15,014,000	8,232,000	58,308,000	106,232,000	63,824,000	33,882,000	75,477,000	83,846,000	53,059,000	56,166,000	75,933,000	83,266,000	39,504,000	30,279,000	58,530,000	51,493,000	13,729,000	16,986,000	21,288,000	17,676,000	12,515,000	11,430,000	39,366,000	58,122,000	31,108,000	58,846,000	74,594,000	107,429,000	42,178,000	52,253,000	66,894,000	52,297,000	46,521,000	19,833,000	21,267,000	28,889,000		6,679,000	7,428,000	14,930,000	22,002,000	1,599,000	-4,293,000	11,209,000	11,614,000	4,049,000	2,514,000	9,236,000	10,833,000	-408,000	3,181,000	2,901,000	4,157,000	3,382,000	2,531,000	2,377,000	1,319,000
cash flows from investing activities:
capital expenditures	-224,000	-1,307,000	-345,000	-744,000	-1,457,000	-717,000	-2,377,000	-9,129,000	-3,036,000	-2,015,000	-2,845,000	-13,475,000	-9,429,000	-4,847,000	-4,639,000	-10,057,000	-8,011,000	-8,602,000	-6,160,000	-15,181,000	-10,511,000	-14,524,000	-10,464,000	-8,414,000	-8,880,000	-7,752,000	-4,111,000	-4,596,000	-3,500,000	-6,115,000	-5,782,000	-3,385,000	-5,326,000	-11,945,000	-17,142,000	-11,338,000	-29,215,000	-16,435,000	-24,685,000	-16,749,000	-19,309,000	-19,423,000	-11,005,000	-12,123,000	-9,394,000	-11,784,000		-3,254,000																					-323,000	-474,000	-308,000
free cash flows	27,917,000	-2,942,000	68,916,000	64,300,000	54,433,000	-201,654,000	2,198,000	-187,749,000	49,931,000	20,631,000	-6,553,000	20,469,000	-11,339,000	969,000	-18,302,000	4,957,000	221,000	49,706,000	100,072,000	48,643,000	23,371,000	60,953,000	73,382,000	44,645,000	47,286,000	68,181,000	79,155,000	34,908,000	26,779,000	52,415,000	45,711,000	10,344,000	11,660,000	9,343,000	534,000	1,177,000	-17,785,000	22,931,000	33,437,000	14,359,000	39,537,000	55,171,000	96,424,000	30,055,000	42,859,000	55,110,000		43,267,000																					3,059,000	2,057,000	2,069,000
capitalized software	-7,949,000	-8,658,000	-9,600,000	-17,783,000	-20,010,000	-17,328,000	-18,144,000	-9,961,000	-22,755,000	-26,721,000	-28,556,000	-86,190,000	-55,222,000	-28,600,000	-12,036,000	-32,285,000	-36,760,000	-32,227,000	-31,816,000	-35,497,000	-37,571,000	-34,011,000	-32,478,000	-32,888,000	-21,972,000	-15,134,000	-16,568,000	-11,012,000	-12,369,000	-9,315,000	-12,343,000	-10,269,000	-8,905,000	-9,144,000	-11,564,000	-10,946,000	-11,645,000	-7,871,000	-3,625,000	-12,404,000	-13,668,000	-13,268,000	-14,219,000	-16,206,000	-14,002,000	-16,321,000		-4,922,000
cash paid for business acquisitions, net of cash acquired	0	0	-24,106,000					0	0			-23,443,000	-11,718,000	0	166,640,000	-164,832,000	-70,021,000	-109,020,000	-168,002,000	-50,333,000	0	-3,975,000	-59,596,000	-29,740,000							0	-20,180,000	0	0	0	0	-73,000	-148,802,000
sale of businesses and other investments, net of cash divested, and distributions received	10,000	671,405,000	1,083,000	61,225,000
purchases of equity securities, other investments and related intangible assets	-1,091,000	-251,000	0	0	-2,200,000	0	-221,000					-7,191,000	-1,159,000		-14,211,000	0			-183,000	-4,100,000	-1,323,000	0	-500,000	0
net cash from investing activities - continuing operations	-9,254,000	661,189,000	-32,968,000	42,698,000	-20,328,000	-15,556,000	-18,989,000					-130,285,000	-77,519,000	-33,410,000
net cash from investing activities - discontinued operations	0	-4,017,000	-11,231,000	0	0	0	0					0	0	0
net cash from investing activities	-9,254,000	657,172,000	-44,199,000	42,698,000	-20,328,000	-15,556,000	-18,989,000	1,680,120,000	-24,226,000	-6,277,000	-34,429,000	-130,285,000	-77,519,000	-33,410,000	481,334,000	-212,803,000	129,294,000	-149,812,000	-206,161,000	-104,896,000	-49,405,000	-52,510,000	-103,038,000	-71,042,000	-956,551,000	-23,375,000	-23,811,000	-15,717,000	-234,570,000	-14,868,000	-18,115,000	-41,270,000	-22,320,000	-26,983,000	-28,670,000	-22,273,000	-40,605,000	-160,592,000	-28,300,000	-29,110,000	-32,951,000	-32,676,000	-25,212,000	-28,318,000	-12,084,000	-30,060,000		-8,111,000																11,884,000	-2,035,000	4,861,000	3,298,000		-43,244,000	2,767,000	-4,792,000
cash flows from financing activities:
taxes paid related to net share settlement of equity awards	-4,795,000	-14,596,000	-13,275,000	-56,000	-80,000	-7,915,000	-5,972,000	-444,000	-56,000	-2,359,000	-3,174,000	-6,762,000	-6,695,000	-5,327,000	-703,000	-153,000	-114,000	-8,496,000	-492,000	-223,000	-690,000	-5,864,000	-825,000	-16,000	-3,217,000	-4,146,000	-1,348,000	-181,000	-3,326,000	-2,207,000	-1,509,000	-329,000	-5,378,000	-3,184,000	-1,848,000	-1,224,000	-5,012,000	-1,648,000	-5,940,000	-731,000	-1,323,000	-2,298,000	-9,277,000
credit facility payments	0	-175,000,000	-25,000,000	-25,000,000	-50,000,000	0	0	-1,140,000,000	-7,500,000	-87,500,000	-80,000,000	-15,000,000	-10,000,000	-5,000,000	-453,273,000	-43,044,000	-216,217,000	-1,217,000	-27,467,000	-4,342,000	-24,213,000	-86,726,000	-76,738,000	-29,145,000	-23,198,000	-28,164,000	-48,599,000	-148,629,000	-20,658,000	-20,625,000	-23,125,000	-10,625,000	-32,813,000	-30,313,000	-35,312,000	-2,814,000	-543,853,000	-27,614,000	-17,615,000	-29,214,000	-179,523,000	-24,522,000	-9,928,000	-45,491,000	-25,490,000	-89,515,000		-10,000,000
credit facility borrowings, net of issuance costs	0	-2,665,000	25,000,000	0	0	250,000,000	0	230,000,000	388,625,000	75,000,000	210,000,000	249,241,000	180,000,000	120,000,000	-66,650,000	221,650,000	130,000,000	145,843,000	185,000,000	69,698,000	40,000,000	80,000,000	169,400,000	55,000,000							10,000,000	36,964,000	40,000,000	15,000,000	50,000,000	0	281,940,000	129,043,000	-25,000	-150,000	324,185,000	0	0	-169,000	0	47,362,000
repurchase of common stock	-33,659,000	-93,693,000	-49,679,000	-108,490,000	-200,000,000	-108,953,000	0	-79,581,000	-45,568,000	0	-9,714,000	-102,160,000	-65,070,000	-65,070,000	-37,023,000	0	-44,306,000	-57,599,000	0	0	-12,077,000	0	-50,159,000	-19,007,000	-14,558,000	-37,517,000									0	0	0	0	0	0	-225,414,000	-547,000	-1,411,000	0			0
intercompany to/from parent/subsidiaries	0	0	11,685,000
payment of acquisition and other financing obligations	0	0	0	0	0	-858,000	-1,542,000	0	0	-1,458,000	-2,911,000	-11,473,000	-1,473,000
net cash from financing activities - continuing operations	-38,454,000	-285,954,000	-51,269,000									50,373,000	42,630,000	-9,516,000
net cash from financing activities - discontinued operations	0	0	-11,697,000									0	0	0
net cash from financing activities	-38,454,000	-285,954,000	-62,966,000	-133,546,000	-50,080,000	-67,726,000	-7,514,000	-1,190,025,000	-9,499,000			50,373,000	42,630,000	-9,516,000	-402,371,000	176,841,000	-140,166,000	72,713,000	152,939,000	61,182,000	69,000	-15,605,000	39,300,000	4,702,000	891,133,000	-69,864,000	-33,954,000	-8,104,000	192,181,000	-7,858,000	-17,181,000	25,911,000	2,792,000	-15,802,000	13,280,000	-1,659,000	11,128,000	109,184,000	-19,383,000	-29,611,000	-80,427,000	-25,483,000	-9,201,000	-43,054,000	-69,938,000	-21,446,000		-11,299,000			-33,035,000	-12,451,000	396,000	1,374,000	293,000	51,466,000	732,000	5,432,000	2,491,000	4,614,000	5,453,000	1,789,000	122,418,000	469,000	3,383,000	3,475,000	2,091,000	1,455,000	68,851,000	1,037,000	1,083,000	299,000
effect of exchange rate changes on cash and cash equivalents	0	-717,000	-11,000	4,000	-545,000	92,000	-27,000	1,080,000	470,000	375,000	-713,000	-103,000	143,000	163,000	-296,000	-37,000	-356,000	65,000	64,000	200,000	177,000	419,000	-749,000	-123,000	-209,000	549,000	-26,000	-822,000	167,000	-497,000	-369,000	-275,000	212,000	123,000	-122,000	223,000	-2,197,000	314,000	-155,000	912,000
net increase in cash and cash equivalents	-19,567,000			-25,800,000	-15,063,000	-284,127,000	-21,955,000	312,555,000	19,712,000	-6,934,000	74,593,000				65,004,000			-18,726,000	53,074,000			7,781,000	19,359,000	-13,404,000	-9,461,000	-16,757,000	25,475,000	14,861,000	-11,943,000	35,307,000							-20,244,000	-11,728,000				17,927,000	72,975,000	-30,893,000	-29,775,000	16,043,000	27,653,000	27,111,000	3,797,000	13,690,000	1,300,000	969,000	20,345,000						1,760,000					23,186,000	940,000	11,517,000	8,290,000	-30,356,000	28,989,000	6,335,000	-1,332,000
cash, cash equivalents and restricted cash, beginning of period	0	0	190,520,000	0	0	0	537,465,000	0	0	0	137,539,000	184,795,000	184,795,000	184,795,000	0	0	0	162,498,000	0	0
cash, cash equivalents and restricted cash, end of period	-19,567,000	368,866,000	152,605,000	-25,800,000	-15,063,000	-284,127,000	515,510,000	312,555,000	19,712,000	-6,934,000	212,132,000	138,724,000	148,139,000	147,848,000	65,004,000	-20,985,000	-2,996,000	143,772,000	53,074,000	20,310,000
less: cash and cash equivalents attributable to discontinued operations	12,000,000
cash, cash equivalents and restricted cash, end of period, excluding discontinued operations	-7,567,000											138,724,000	148,139,000	147,848,000
other (income) loss								-5,111,000	-732,000
equity in net income (income) of unconsolidated investments			398,000		257,000													61,000
other loss			226,000																																											2,031,000
net decrease in cash and cash equivalents			-37,915,000									-46,071,000	-36,656,000	-36,947,000																	15,828,000	-1,905,000	-2,330,000	-21,374,000						-26,701,000
less: cash and cash equivalents and restricted cash included in current assets held for sale			-68,518,000
cash, cash equivalents and restricted cash, end of period, excluding current assets held for sale			84,087,000
accrued doj settlement				0	0	0	0	-58,424,000	-15,725,000	-15,731,000	-57,289,000
other proceeds from investing activities								0	0	0	0	14,000	9,000	5,000	-10,000	19,000	8,000	37,000	0
proceeds from issuance of 0.875% convertible senior notes
payments for issuance costs on 0.875% convertible senior notes						0	0	0	0	0	-758,000
payments for capped call transaction on 0.875% convertible senior notes
repayment of convertible senior notes				0	0			0	-345,000,000
purchases of subsidiary shares owned by non-controlling interest								0	0	0	0	-54,064,000	-54,064,000	-54,064,000
asset impairment charges								74,759,000	210,000	0	0	4,037,000	3,789,000	98,000	28,091,000	0			0	0	0	0	0	0	0	4,650,000	1,203,000	22,000	293,000	26,000	256,000	188,000	1,751,000	195,000	950,000				0
impairment of long-term investments															0	0
cash received from sale of businesses, net of cash divested
sale of other investments						166,000	1,753,000
distributions received from investments
accelerated share repurchase program
operating right-of-use asset amortization							5,019,000	4,571,000	5,277,000	5,241,000	5,631,000	16,722,000	11,007,000	5,320,000
other loss (income)							1,752,000				287,000	2,796,000
operating leases							-4,143,000	-4,157,000	-4,782,000	-4,153,000	-6,174,000	-17,897,000	-11,874,000	-5,854,000
goodwill impairment charge
proceeds from sale or issuance of common stock												0	0	0	0	1,071,000	0	212,000	1,568,000	0	0	0	0	79,000	0	5,000	1,540,000	659,000
impairment (recovery) of long-term investments									1,025,000
equity in net (income) loss of unconsolidated investments									-383,000										-115,000	-449,000	28,000	-285,000
sales (purchases) of equity securities, other investments and related intangible assets									1,565,000					32,000
repurchase of unsettled common stock												-9,301,000
recovery of long-term investments											0
(purchases) sales of equity securities, other investments and related intangible assets											-3,028,000
net cash provided (used in) by financing activities											113,443,000
cash received from sale of businesses												0	0		566,611,000	-5,648,000
less: cash and cash equivalents within current assets attributable to discontinued operations
software development costs
less: accumulated amortization
(recovery) impairment of long-term investments												-1,045,000	-1,045,000	-1,045,000
payments of lease obligations												-108,000	-68,000	-55,000
less: cash and cash equivalents included in current assets attributable to discontinued operations												0	0	0
revenue related to deferred revenue balance at beginning of period												126,184,000	126,184,000
revenue related to new performance obligations satisfied during the period												248,221,000	248,221,000
revenue recognized under "right-to-invoice" expedient												55,923,000	55,923,000
reimbursed travel expenses, shipping and other revenue												1,721,000	1,721,000
total revenue												432,049,000	432,049,000
other (income) losses													1,992,000
loss on sale of businesses														0
other income (losses)														172,000
payment of acquisition financing obligations														0	-1,419,000	0	0	-3,226,000	-2,480,000
other (losses) income															-8,978,000
excess tax benefits from stock-based compensation															0				0	0	0	0	-42,000	-10,000	-765,000	-197,000	-298,000	-13,000	-331,000	-2,000	2,246,000	-28,000	-1,086,000	-1,132,000	-591,000	-803,000	-839,000	-1,654,000	-2,907,000	-508,000	0	-101,000	-4,130,000	2,363,000	-2,875,000	-4,176,000	11,839,000	1,269,000
payments of capital lease obligations															7,518,000	-2,683,000	-2,584,000	-2,804,000	-3,190,000	-3,047,000	-2,951,000	-3,015,000	-2,419,000	-2,220,000	-1,399,000	-239,000	-287,000	-174,000	-69,000	-68,000	-118,000	-114,000	-113,000	-110,000	-42,000	-116,000	-118,000	-182,000	-187,000	-204,000	-199,000	-232,000	-353,000	-356,000	-352,000	-366,000		-303,000																					-23,000	2,000	-7,000
write-off of unamortized deferred debt issuance costs - netsmart
(purchases) sales of subsidiary shares owned by non-controlling interest
other losses																	-415,000	50,000	294,000	1,417,000	1,054,000	1,240,000		1,094,000	5,405,000	3,059,000	631,000	1,238,000	85,000	965,000									1,612,000	-335,000	1,044,000	86,000	828,000	454,000
impairment of and losses on long-term investments																		5,500,000	0
write-off of unamortized deferred debt issuance costs
accounts receivable																			-68,175,000	-18,209,000	-5,037,000	-8,010,000	-5,103,000	-316,000	-157,000	-12,250,000	-3,845,000	-4,127,000	5,943,000	5,244,000	7,643,000	1,090,000	4,801,000	-28,178,000	-18,671,000	16,871,000	5,000,000	-10,905,000	34,267,000	-7,948,000	11,957,000	-12,103,000	5,958,000	-17,466,000	-39,215,000	-5,189,000		-27,380,000	-6,417,000	3,908,000																			-1,855,000	-1,552,000	982,000	-2,561,000
proceeds from issuance of redeemable convertible preferred stock - netsmart																			0	0			-1,000	1,000
proceeds from sales of subsidiary shares to non-controlling interest																			0
proceeds received from sale of fixed assets																					0	0	0	0	26,000	11,000	0	0	8,000	7,000									0	0			0
cash and cash equivalents, beginning of period																						96,610,000	0	0	0	116,873,000	0	0	0	53,173,000	0	0	0	62,954,000	0	0	0	103,956,000	0	0	0	157,753,000	0	0	0	129,403,000		0	0	71,159,000		0	0	0	43,785,000		0	0	42,461,000		0	0	60,905,000		0	0	16,972,000		0	0	13,336,000
cash and cash equivalents, end of period																						104,391,000	19,359,000	-13,404,000	-9,461,000	100,116,000	25,475,000	14,861,000	-11,943,000	88,480,000	15,828,000	-1,905,000	-2,330,000	41,580,000	2,164,000	-11,194,000	-20,244,000	92,228,000	10,284,000	-26,701,000	-55,307,000	175,680,000	72,975,000	-30,893,000	-29,775,000	145,446,000		27,111,000	3,797,000	84,849,000		969,000	20,345,000	7,123,000	43,721,000		-8,408,000	-3,845,000	44,221,000		2,756,000	-2,247,000	35,225,000		940,000	11,517,000	25,262,000		28,989,000	6,335,000	12,004,000
supplemental non-cash information:
accretion of redemption preference on redeemable convertible non-controlling interest in netsmart																						10,962,000
obligations to enter into capital leases																						1,407,000
other losses (gains)																																858,000	949,000	1,407,000
sales and maturities of marketable securities and other investments																							0	0	0	0	0	2,458,000	0	1,305,000									10,000	43,000	26,000	15,000	12,000	11,000	-9,000	41,000
exchange of netsmart, inc. common stock for redeemable convertible preferred stock in netsmart by netsmart, inc. management																								0
purchase of controlling interest, net of cash acquired																										0	0	0
purchases of non-marketable securities, other investments and related intangible assets																										-500,000	-3,132,000	-2,567,000	-209,337,000	-750,000
credit facility borrowings																										0	14,442,000	140,208,000	114,511,000	15,000,000
proceeds from issuance 1.25% senior cash convertible notes, net of issuance costs																															0	0
purchase of call option related to 1.25% senior cash convertible notes																															0	0			0	0
proceeds from issuance of warrants, net of issuance costs																															0	0
payments of acquisition financing obligations																															0	0			0	0
proceeds from issuance of common stock																														40,000	-183,000	-13,000	10,000	1,673,000	191,000	1,992,000	1,333,000	7,931,000	1,477,000	180,000	1,847,000	2,015,000
changes in operating assets and liabilities, net of business combinations:
purchases of marketable securities, other investments and related intangible assets																															0	-7,470,000	-8,106,000	-5,968,000
sales and maturities of other investments																																10,000	10,000	19,000	36,000	11,000	328,000	12,516,000
proceeds from sale of fixed assets																																24,000	7,000	55,000
change in fair value of 1.25% call option and cash conversion option																																		56,000	42,000
purchases of marketable securities and other investments																																							0	0	0	0	0	0	-8,679,000	-4,221,000
change in restricted cash																																							0	0	0	0	0	0	0	2,225,000
other (gains) losses																																						-8,256,000
proceeds from issuance of 1.25% senior cash convertible notes, net of issuance costs
proceeds from issuance of warrants, net of issuance cost
proceeds from issuance of warrants
changes in operating assets and liabilities, net of business combinations
net cash acquired in merger with eclipsys																																											0
changes in operating assets and liabilities:
inventories																																								-460,000	1,391,000	-634,000	-39,000	1,173,000	-619,000	1,242,000		116,000	-1,398,000	259,000										362,000			475,000	-239,000	-6,000	240,000	203,000	41,000	252,000	125,000	459,000	33,000
benefit from doubtful accounts																																										5,110,000	2,495,000	2,789,000	2,774,000	2,001,000	1,943,000	3,162,000	1,801,000	879,000	1,290,000	1,188,000	663,000	2,046,000	1,014,000	817,000	410,000	559,000	818,000	857,000	852,000	1,147,000	324,000	202,000	-79,000	328,000	102,000	276,000	298,000	-105,000	-18,000	138,000
effect of exchange rates on cash and cash equivalents																																										1,492,000	-41,000	-1,699,000	-6,000	655,000
asset impairment losses																																															0
loss on sale of prepackaged medications business
payment for acquisition of allscripts																																															0
net cash acquired in merger with allscripts																																															0				0	0
net proceeds received from sale of building																																															0				0	0
net proceeds received from sale of prepackaged medications business
payments on promissory note																																															0
line of credit payments																																															0
line of credit borrowings																																															0				0	0
change in parent’s net investment, including 330,000 received from misys plc																																															0				5,302,000	5,246,000
repurchase of senior convertible notes																																															0
net proceeds from stock-based compensation activities																																												6,825,000
proceeds from employee stock purchase plan																																												679,000	635,000	559,000	330,000	500,000	329,000	566,000	423,000		214,000	180,000	175,000	224,000	195,000	203,000	267,000	172,000
net proceeds received from sale of fixed assets
net proceeds (payments) from stock-based compensation activities																																														16,338,000
other gains
purchases of marketable securities																																																-5,000
net proceeds from the sale of the prepackaged medications business
proceeds from exercise of common stock options																																															252,000	-227,000	1,033,000	811,000	3,830,000	536,000	182,000	1,194,000	118,000			5,229,000	2,224,000	4,442,000	5,310,000	2,105,000	2,520,000
change in parent’s net investment
other long-term assets
purchase of preferred shares in imedica
cash and cash equivalents, beginning of year
cash and cash equivalents, end of year
sales and maturities of marketable securities																																																70,000	172,000	4,185,000	7,062,000	1,505,000
purchase of marketable securities																																																																					-41,776,000	-2,200,000	-16,935,000
accrued compensation																																																					-1,519,000							487,000	5,581,000							813,000	156,000	645,000	-1,208,000
other current liabilities
payments for other acquisitions
asset impairment loss																																																				0
inventory
other non-current liabilities
payments for acquisition of allscripts
payment on promissory note
payment of capital lease obligation
payment of credit facility
net income from continuing operations, net of tax
net income from discontinued operations, net of tax
gain on sale of equity investment
realized loss on investments																																																					1,000	7,000	5,000		6,000	23,000	12,000		8,000	8,000	118,000
gain on sale of physicians interactive business
sale of equity investment																																																									0
net payments for purchase of extended care information network, inc.
net payments for purchase of a4 health systems, inc.
net payments for other acquisitions and related transaction costs
net proceeds from sale of physicians interactive business
maturities of marketable securities																																																						2,406,000	1,479,000	26,739,000	3,670,000	7,469,000	3,904,000	9,690,000	8,394,000	2,277,000	53,665,000	19,733,000	12,596,000	9,616,000	9,927,000	16,906,000	889,000	6,731,000	13,773,000	17,797,000
net payments for purchase of extended care information systems, inc.
write-off of capitalized software																																																												0	0	0	290,000
realized (gain) loss on investments																																																																8,000	20,000	14,000	9,000			41,000	-113,000
capitalized software and website development costs																																																																					-934,000	-1,151,000	-1,322,000
investment in promissory note receivable and minority interest
sale of equity investment.
net payments for purchase of a4 health sytems, inc.
net proceeds received in issuance of common stock																																																												0	1,000	-317,000	140,991,000
repurchase of common stock from a related party
net proceeds from revolving credit facility
investment in promissory note receivable
payment for a4 health systems, inc. and related transaction costs
payments for other acquisitions and related transaction costs
net proceeds from exercise of common stock options
non-cash investing and financing information:
common stock issued in connection with the acquisition of a4 health systems, inc.																																																													0	0	68,775,000
assumption of secured promissory note in connection with the a4 acquisition																																																													0	0	3,400,000
issuance of common stock from treasury																																																															11,250,000
accrued restructuring and other charges																																																																							-75,000
payments for a4 health systems, inc. and related transaction costs
debt issuance costs
issuance of convertible debt
purchase of treasury stock
other receivables																																																													-69,000	12,000	340,000	63,000			20,000		-83,000	-84,000	8,000	132,000
payment for purchase of a4 health systems, inc. and related transaction costs
repurchase of common stock from related party
supplemental disclosure of cash flow information:
payment of interest on long term debt																																																															1,444,000
payments for acquisitions																																																																					0
proceeds from exercise of stock options																																																																	3,417,000	1,958,000	3,623,000		472,000	1,035,000	1,090,000
payment of interest on long-term debt																																																																	1,444,000
payment of state income taxes																																																																	0
restructuring and other charges
non-cash compensation expense																																																																								0
realized gain on investments
changes in operating assets and liabilities, net of effects of acquisitions:
payments for acquisitions, net of cash acquired
proceeds from issuance of long-term debt
proceeds from issuance of common stock, net of transaction costs
write-off of acquired in-process research and development
asset impairment charge
capitalized software development costs
proceeds from exercise of common stock options and warrants
changes in assets and liabilities, net of effects of acquisitions:
prepaid expenses and other current and non-current assets
cash paid during the period for interest

We provide you with 20 years of cash flow statements for Allscripts Healthcare Solutions stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Allscripts Healthcare Solutions stock. Explore the full financial landscape of Allscripts Healthcare Solutions stock with our expertly curated income statements.

The information provided in this report about Allscripts Healthcare Solutions stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.